Credit Analysis: PHYNOVA GROUP LIMITED

1. Credit Opinion: DECLINE

Reasoning: Phynova Group Limited presents an unacceptable credit risk for standard commercial lending facilities. The company is deeply insolvent on both a net assets basis (-£5.82M) and a shareholders' funds basis (-£36.45M), with severe working capital deficiencies. The going concern basis is explicitly dependent on future equity fundraising and revenue growth—neither of which provides certainty of repayment. The company has sustained cumulative losses over many years, with no profit and loss account disclosed to assess recent trading performance. This profile is inconsistent with acceptable credit risk for debt facilities.

2. Financial Strength

Balance Sheet Position: Critically Weak

The balance sheet is fundamentally impaired. Shareholders' funds have deteriorated from a positive position of £15.2M (2016) to negative £36.5M (2024), reflecting sustained and significant trading losses over approximately eight years. The company is technically insolvent on both a net assets and net current assets basis.

The marginal improvement in shareholders' funds (£24k) suggests the 2024 loss may have been smaller than in prior years, but without the P&L account (exempt under small companies regime), we cannot verify profitability trends. The continued erosion of net assets—worsening by £218k year-on-year—remains concerning.

Capital Structure: The share premium account of £26.5M against called-up share capital of £3.9M indicates substantial equity investment over time, all of which has been consumed by accumulated losses reflected in the P&L reserve deficit of £36.5M.

3. Cash Flow Assessment

Liquidity Position: Precarious but Currently Funded

Cash has improved meaningfully, which is the only positive signal. However, current liabilities exceed current assets by £4.93M, creating a severe working capital shortfall. The company cannot meet its current obligations from current assets without external funding.

Key Concerns: - Stock buildup: The 65% increase in stocks (£579k → £955k) requires assessment—this could indicate preparation for sales growth or, conversely, slow-moving/obsolete inventory in an R&D business - Debtor reduction: The 38% decrease in debtors may reflect improved collections or reduced sales volumes - Creditor pressure: Current liabilities growing by 10% suggests trade creditors or group liabilities are increasing, potentially indicating stretched payment terms - Long-term creditors: Static at £1.22M (unchanged from 2023), likely group-related debt

The going concern note explicitly states reliance on the Enterprise Investment Scheme (EIS), which is "largely used up" at the £20M cap, and future dependence on "generating and growing revenue" and "issuing new shares outside of the EIS scheme." This is a clear admission that the company cannot sustain itself from operating cash flows alone.

4. Monitoring Points

If any exposure exists or is being considered despite the decline recommendation, the following require close monitoring:

1. Revenue and Gross Profit Trends: Without filed P&L data, request management accounts to assess whether the company's claim of "generating a gross profit" translates to operating profitability or merely covers cost of sales

2. Cash Runway: At current cash of £1.62M against monthly burn rate (unknown), monitor cash position quarterly. The 2023→2024 cash improvement of £457k should be interrogated—was this from trading, share issuance, or group funding?

3. Equity Fundraising Progress: Track whether new share issuances outside EIS are being executed. Failure to raise would likely trigger insolvency

4. Creditor Payment Behaviour: Monitor trade creditor days and whether the company is stretching supplier terms to preserve cash

5. Group Structure: The company holds £326k in subsidiary investments. Understand the group structure—obligations to/from group entities may represent further contingent liabilities

6. Stock Realisability: The significant stock increase requires validation. In an R&D/natural sciences company, inventory obsolescence risk is elevated

7. Director Changes: Note the current directors (Kshetrapal, Stacey, Ducroux) differ from the signatory (K Thomson). Monitor board stability and any director departures